Key result
Tanshinone IIA suppresses inflammation and fibrosis across multiple pathways to counter cardiovascular disease.
Why the study?
Vascular diseases are often initiated by endothelial dysfunction accompanied by inflammation and fibrosis, and Tanshinone IIA has gained attention for its potential activity against cardiovascular disorders.
This review highlights the mechanistic pathways through which Tanshinone IIA targets endothelial dysfunction, supporting its therapeutic potential in the management of cardiovascular diseases.
Tanshinone IIA may target cardiovascular inflammation and fibrosis; leaves open clinical adoption pending randomized trials.
Salvia miltiorrhiza Burge (Danshen), a member of the Lamiaceae family, has been used in traditional Chinese medicine for many centuries as a valuable medicinal herb with antioxidative, anti‐inflammatory, and antifibrotic potential. Several evidence‐based reports have suggested that Salvia miltiorrhiza and its components prevent vascular diseases, including myocardial infarction, myocardial ischemia/reperfusion injury, arrhythmia, cardiac hypertrophy, and cardiac fibrosis. Tanshinone IIA (TanIIA), a lipophilic component of Salvia miltiorrhiza , has gained attention because of its possible preventive and curative activity against cardiovascular disorders. TanIIA, which possesses antioxidative, anti‐inflammatory, and antifibrotic properties, could be a key component in the therapeutic potential of Salvia miltiorrhiza . Vascular diseases are often initiated by endothelial dysfunction, which is accompanied by vascular inflammation and fibrosis. In this review, we summarize how TanIIA suppresses tissue inflammation and fibrosis through signaling pathways such as PI3K/Akt/mTOR/eNOS, TGF‐ β 1/Smad2/3, NF‐ κ B, JNK/SAPK (stress‐activated protein kinase)/MAPK, and ERK/Nrf2 pathways. In brief, this review illustrates the therapeutic value of TanIIA in the alleviation of oxidative stress, inflammation, and fibrosis, which are critical components of cardiovascular disorders.
No takes yet. Share an insight, caveat, or question.
Lu et al. (2022) conducted a review in Cardiovascular diseases, tissue inflammation, and fibrosis. Tanshinone IIA was evaluated. Tanshinone IIA, a component of Salvia miltiorrhiza, suppresses tissue inflammation and fibrosis through multiple signaling pathways, offering therapeutic potential for cardiovascular disorders.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: